HSD3B1 in prostate cancer prognosis and treatment
Abstract Inherited variation in HSD3B1 , which encodes 3β-hydroxysteroid dehydrogenase type 1, alters the stability of a key enzyme in peripheral steroid metabolism and offers a compelling mechanism for continued androgen production during prostate cancer treatment. The adrenal-permissive rs1047303 allele has been associated with poorer outcomes after androgen deprivation, particularly in some patients with low-volume metastatic disease. Yet its clinical significance is not uniform across disease stages, ancestral populations or modern treatment regimens. Biomarker analyses from randomized trials show that treatment intensification with enzalutamide provides benefit across HSD3B1 genotypes, without convincing evidence that the variant modifies relative treatment efficacy. Studies of castration-resistant disease are further complicated by differences in prior treatment, genetic models and clinical risk adjustment. HSD3B1 also participates in abiraterone metabolism, creating opposing pharmacological effects that complicate simple predictions. Here we critically evaluate the mechanistic, clinical and population evidence, distinguish prognostic associations from treatment-predictive biomarkers, and define the evidence needed for prospective clinical implementation. HSD3B1 remains a promising marker of steroid metabolic biology, but current evidence does not justify genotype-guided selection or withholding of established systemic therapies.
Authors
- Amit V. Pandey (ORCID: https://orcid.org/0000-0001-8331-5902)
- Jibira Yakubu Yakubu
Publication Details
- Journal
- Research Square
- Published
- 2026-11-17
- DOI
- https://doi.org/10.21203/rs.3.rs-11732724/v1
- Primary Topic
- Prostate Cancer Treatment and Research
- Type
- preprint